Mounting Evidence Supports Promise of JAK Inhibitor Treatment for Refractory Dermatomyositis
Recent research suggests JAK inhibitors, specifically tofacitinib, may be useful in the management of refractory dermatomyositis. With Ted Rosen, MD, FAAD In 2016, dermatologists from Harvard Medical School published what they described as the first report of the successful use of the Janus kinase (JAK)-1/3 inhibitor, tofacitinib, to treat refractory cutaneous dermatomyositis (DM).1 Based on […]